Neurology News

A clinical-stage genetic medicine firm has announced $60 million in Series B financing to support a phase 1/2 clinical trial and advance its lead candidate to treat spinocerebellar ataxia types 1 and 3 as well as Huntington’s disease.

The European Medicines Agency has approved enrollment for a phase 1/2a biomarker study to examine a once-daily, oral, brain penetrant mitochondrial stimulator to treat a range of neurological and neuromuscular conditions.

Performance Vision Technologies has launched Altius advanced performance-tinted contact lenses, the second generation to Nike MaxSight, in the U.S. and select international markets.

Primary care physicians often recommend patients exercise, but because convincing them to get active can be easier said than done, it is often a good idea to start with short daily walks, according to experts.

Combination behavioral and pharmaceutical therapy improved functionality and daytime symptoms of insomnia, while addition of a second treatment provided further benefits for the condition, according to research from JAMA Network Open.

“Why should I be investing in bonds when I can earn more than 5% on my cash?” Many investors, including physicians, are asking this question after being discouraged by losses they have experienced with bonds in recent years.

Hearing loss was linked to a higher risk for dementia, and this risk was greater among people who did not use a hearing aid than those who did, a recent study in JAMA Otolaryngology – Head and Neck Surgery found.

Vanqua Bio has announced its lead candidate for Parkinson’s disease, a small molecule allosteric activator of glucocerebrosidase, will enter clinical development in the first quarter of 2024.

Surgical procedures targeting vagus nerve stimulation for those with drug-resistant epilepsy are generally safe with low incidence and rate of complications, according to research from Brain and Spine.

A clinical-stage biopharma firm announced it has been granted a U.S. patent expanding coverage of a novel oral therapy to treat various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein.